Skip to content
lifestyle.socialsinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immunocore Holdings plc
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
September 14, 2026
Immunocore to present at upcoming investor conferences
September 1, 2026
Immunocore reports second quarter financial results and provides a business update
August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
July 30, 2026
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
May 31, 2026
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
May 25, 2026
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
May 23, 2026
Immunocore reports first quarter financial results and provides a business update
May 7, 2026
Immunocore to present at upcoming investor conferences
March 3, 2026
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
February 25, 2026
1
2
Next Page
→